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SUMMARY 
As part of CDC’s National Notifiable Disease Surveillance System (NNDSS), viral hepatitis 
case-reports are received electronically from state health departments via CDC’s National 
Electronic Telecommunications System for Surveillance (NETSS), a computerized public health 
surveillance system that provides CDC with data regarding cases of nationally notifiable diseases 
on a weekly basis. Although surveillance infrastructure is in place for reporting of acute 
infection, reports of chronic hepatitis B and C, which account for the greatest burden of disease, 
are not submitted by all states. As noted in a report from the Institute of Medicine (1), 
surveillance capacity to monitor both acute and chronic viral hepatitis is limited at the state and 
local levels, resulting in underreporting and variable data quality.  
Data in this report should be interpreted with the consideration that reported cases of acute or 
chronic viral hepatitis represent only those relatively few infected persons who were detected, 
diagnosed, met a stringent case definition, and eventually reported to CDC in 2012. Because 
most acute and chronic infections are not reported, this Summary is mainly useful in detecting 
major trends in viral hepatitis A (HAV), B (HBV) and C (HCV). In 2011 and 2012 a major effort 
was undertaken to improve methodologies for estimating total number of new cases of hepatitis 
A, B and C from the number of cases reported for each disease (2). Estimates in this report of 
incidence of new infections were obtained using the newly improved methodology (2). These 
estimates cannot be compared to previous years’ estimates that were obtained using different 
(unpublished) procedures; however, trends seen in reported data still pertain, such as the increase 
in acute HCV infection among young persons that was observed in 2011. 
Because chronic HBV and HCV infection are largely hidden and part of what the former United 
States Assistant Secretary for Health, Dr. Howard Koh has dubbed the “Silent Epidemic” (3), 
this report also provides data to inform our understanding of the current epidemic of chronic 
hepatitis B and C. 
With progressive infant vaccination recommendations since 1996—and universal infant 
vaccination since 2006--vaccination rates and evidence of vaccine-induced immunity in young 
patients have been increasing continuously in the past decade (4, 5). Half of all hepatitis A 
infections now apparently are acquired outside the United States by adult travelers (6). The 
major public health demands regarding hepatitis A relate to newly discovered HAV-infected 
food handlers, as these place a large burden on local public health departments to notify, test, and 
vaccinate potentially infected restaurant patrons (7). There were 1,562 reported cases of acute 
HAV in 2012. After asymptomatic infections and under-reporting were taken into account (2), it 
was estimated that approximately 3,050 new infections occurred in 2012.  
Acute hepatitis B has been declining in incidence since 1990 mainly due to effective vaccination 
strategies, but chronic HBV infection, estimated at 700,000-1.4 million of the US population (8, 
9), remains a major public health challenge. As the surveillance data in this report and other data 
indicate, about one-half of all chronic HBV infections are among persons born in Asia and 
Asian-Americans who were born to HBV-infected mothers in the United States. Identifying 
these chronically infected persons and linking them to care remains a challenge (10, 11). There 
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were 2,895 cases of acute hepatitis B reported in 2012. After adjusting for asymptomatic 
infections and under-reporting (2), the estimated number of new HBV infections was 18,760.  
After receiving reports of approximately 800-1,000 cases of acute hepatitis C each year from 
2006-2010, there was a significant increase of 45% in reported cases of acute HCV infection 
from 2010-2011, and a 75% increase from 2010-2012.  Cases of acute HCV infection rose from 
850 in 2010 to 1,229 in 2011 and to 1,778 in 2012.  After adjusting for asymptomatic infections 
and under-reporting (2), 21,870 new infections of HCV occurred in 2012. This increase is 
thought to reflect a trend in new cases among adolescents and young adults, particularly in 
Eastern and Midwestern states. Based on epidemiologic studies, these cases of HCV infection 
are predominately among young persons who are white, live in non-urban areas, have a history 
of injection drug use, and previously used opioid agonists such as oxycodone (12, 13). Some of 
the increase in reported acute HCV infection reflects improved ascertainment by selected states 
and local health departments funded by CDC to investigate such cases more actively, for 
example Florida, Massachusetts, New York, Wisconsin, and Philadelphia.  However, in other 
locations where the number of cases has increased very markedly, such as Tennessee, West 
Virginia, and Kentucky, with over 20% of all new cases in the three states combined, the 
increases have occurred without any federal support for investigation or follow up (14)(Table 
4.1).  
Chronic HCV infection affects approximately 3.2 million US residents, after adjustment for 
homeless and incarcerated persons not captured in random household surveys (15). However, 
prevalent chronic infections appear to be declining due, in part, to increasing mortality among 
HCV-infected persons—primarily adults aged 45 to 65 years—mortality that since 2007 has 
exceeded deaths from HIV/AIDS in the United States (16, 17). A major public health challenge 
is to increase the proportion of persons tested and the proportion of those who test positive who 
are referred for care and treatment (10, 11).  
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BACKGROUND 
Viral hepatitis is caused by infection with any of at least five distinct viruses: hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis 
E virus (HEV). Most viral hepatitis infections in the United States are attributable to HAV, HBV, 
and HCV. All three of these unrelated viruses can produce an acute illness characterized by 
nausea, malaise, abdominal pain and jaundice, although many of these acute infections are 
asymptomatic or cause only mild disease. Thus, many persons infected with HBV or HCV are 
unaware they are infected and have clinically silent infections for decades until developing 
cirrhosis, end-stage liver disease, or hepatocellular carcinoma. 
Hepatitis A 
Transmitted through the fecal-oral route, HAV is acquired primarily through close personal 
contact and foodborne outbreaks (18). Since 1995, effective vaccines to prevent HAV infection 
have been available in the United States, increasing the feasibility of eliminating indigenous 
transmission. In 1996, CDC’s Advisory Committee on Immunization Practices (ACIP) 
recommended administration of hepatitis A vaccine to persons at increased risk for the disease, 
including international travelers, men who have sex with men (MSM), non-injection and 
injection-drug users (IDUs), and children living in communities with high rates of disease (19). 
In 1996, ACIP also recommended routine vaccination for children living in 11 states with 
average hepatitis A rates of >20 cases per 100,000 population and recommended that vaccination 
be considered for children in an additional six states with rates of 10–20 cases per 100,000 
population (20). ACIP expanded these recommendations in 2006 to include routine vaccination 
of newborns in all 50 states (4). 
Hepatitis B 
HBV is transmitted by percutaneous or mucosal exposure to the blood or body fluids of an 
infected person, from an infected mother to her newborn during childbirth, through close contact 
within households, through unscreened blood transfusion or unsafe injections in health care 
settings, through injection-drug use, and from sexual contact with an infected person. Adults 
with diabetes mellitus are at an increased risk of acquiring HBV infection. These persons are 
recommended to receive hepatitis B vaccination if younger than 60 years of age and to be 
considered for vaccination if aged 60 years or older (21). 
The risk for chronic HBV infection decreases with increasing age at infection. Of infants who 
acquire HBV infection from their mothers at birth, as many as 90% become chronically infected, 
whereas 30%–50% of children infected at age 1–5 years become chronically infected. This 
percentage is smaller among adults, in whom approximately 5% of all acute HBV infections 
progress to chronic infection (22). 
Effective vaccines to prevent hepatitis B virus infection have been available in the United States 
since 1981. Ten years later, a comprehensive strategy was recommended for the elimination of 
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HBV transmission in the United States (23, 24). This strategy encompassed the following four 
components:  
• Universal vaccination of infants beginning at birth; 
• Prevention of perinatal HBV infection through routine screening of all pregnant women 
for HBV infection and the provision of immunoprophylaxis to infants born either to 
infected women or to women of unknown infection status; 
• Routine vaccination of previously unvaccinated children and adolescents; and  
• Vaccination of adults at increased risk for infection (including health-care workers, 
dialysis patients, household contacts and sex partners of persons with chronic HBV 
infection, recipients of certain blood products, persons with a recent history of having 
multiple sex partners concurrently, those infected with a sexually transmitted disease, 
men who have sex with men [MSM], and injection drug users). 
In addition to hepatitis B vaccination, efforts have been made to improve care and treatment for 
persons who are living with hepatitis B. In the United States, 700,000-1.4 million persons are 
estimated to be infected with the virus (8, 25), many of whom are unaware of their infection 
status (10). To improve health outcomes for these persons, CDC issued recommendations in 
2008 to guide HBV testing and public health management of persons with chronic HBV 
infection (26). These guidelines stress the need for testing persons at high risk for infection, 
conducting contact management, educating patients, and administering FDA-approved therapies 
for treating hepatitis B.  
Hepatitis C 
HCV is transmitted primarily through percutaneous (parenteral) exposure that can result from 
injection-drug use, needle-stick injuries, and inadequate infection control in health-care settings. 
Much less often, HCV transmission occurs among HIV-positive persons, especially MSM, as a 
result of sexual contact with an HCV-infected partner (27, 28), among persons who receive 
tattoos in unregulated settings (28), and among infants born to HCV-infected mothers (29). With 
an estimated 3.2 million chronically infected persons nationwide, HCV infection is the most 
common blood-borne chronic infection in the United States (15). 
Currently a single positive anti-HCV result cannot distinguish between acute and chronic HCV 
infection, and making this distinction requires a health department to follow-up with a provider 
to determine if there were symptoms for reporting purposes.  Laboratory criteria in the 2012 case 
definition for past or present HCV infection require one or more of the following: anti-HCV 
positive (repeatedly reactive) by EIA, verified by at least one more specific assay, or HCV RIBA 
positive, or HCV nucleic acid test (NAT) positive, or anti-HCV screening-test positive with an 
assay-specific signal-to-cutoff ratio predictive of a true case. This assessment requires, on 
average, review of at least 4 records by hepatitis surveillance staff  in health departments (30) No 
clinical symptoms are required; however, the case must be known to not be an acute case. 
Approximately 75%-85% of newly infected persons develop chronic infection. 
Because of the high burden of chronic HCV infection in the United States and because no 
vaccine is available for preventing infection, national recommendations (31) emphasize other 
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primary prevention activities, including screening and testing blood donors, inactivating HCV in 
plasma-derived products, testing persons at risk for HCV infection and providing them with risk-
reduction counseling, and consistently implementing and practicing infection control in health-
care settings. In 2010, the FDA approved point-of-care tests for HCV infection, which meant that 
patients could receive HCV test results within the same visit and faster referral to care (32). In 
2012, CDC augmented existing risk-based recommendations for HCV testing by recommending 
one-time screening for HCV infection among all those born during 1945-1965 (33). It is 
estimated that persons born during these years have a 3% prevalence of HCV antibodies, which 
is five times higher than the prevalence seen in adults born in other years. Of all persons living 
with HCV infection, about 75% were born during 1945-1965; a similar percentage of HCV-
associated deaths can be attributed to this birth cohort (33). The goal of the new birth-cohort 
approach to HCV testing is to identify unrecognized infections among the segment of the 
population with the largest risk of HCV-associated morbidity and mortality, thereby increasing 
opportunities for persons infected with HCV to benefit from appropriate care and treatment. 
Implementation of the birth cohort screening recommendation and point of care testing for HCV 
infection will facilitate testing, notification of results, post-test counseling and referral to care.  
Linkage to care and treatment is critical to improving health outcomes for persons found to be 
infected with HCV. Such linkage is particularly important in light of the major advancements 
that have been made in HCV treatments. For patients infected with HCV, treatment has 
previously consisted of pegylated interferon combined with oral doses of ribavirin, a regimen 
that has improved health outcomes for many infected persons. Approximately 40% of HCV-
infected patients receiving this therapy clear their infection. New direct acting agents against 
HCV (telaprevir, boceprevir) were licensed by the FDA in 2011 and are now standard-of-care. 
These agents, when given in combination with current therapy, can increase virologic cure rates 
to 80% while decreasing duration of therapy (34). Several drugs are now administered orally (a 
major advancement in how treatments are administered for this infection), leading to viral 
suppression in 90% of patients taking one of these new oral medications (35, 36). 
Notes on “Case Classification” 
For analysis at the national level, cases of viral hepatitis are considered “confirmed” if they meet 
both the clinical case definition and laboratory criteria for diagnosis; however, these criteria are 
evaluated at the state or local level and are not validated by CDC. For hepatitis A, cases also are 
considered confirmed if they meet the clinical case definition and involve a person who is 
epidemiologically linked to someone with laboratory-confirmed hepatitis A (e.g., through 
household or sexual contact with an infected person or eating HAV-contaminated food or food 
prepared by an infected foodhandler during the 15–50 days before symptom onset). 
Sources of Information 
CDC relies on several sources of information to determine the incidence, prevalence, trends, and 
burden of viral hepatitis A, B, and C disease. The basis for most case reports is passive 
surveillance through the National Notifiable Disease Surveillance System (NNDSS). State and 
local health departments report acute hepatitis A, B and C (incident cases) through this system. 
However, a number of states do not report cases of chronic hepatitis B and C through the 
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NNDSS. Collecting, verifying and reporting the many chronic cases of hepatitis B and C in the 
United States (estimated at over 4 million) is beyond the capability of many health departments. 
Reports of chronic hepatitis B and C are included in this Surveillance Summary from NNDSS 
from states that gave permission for CDC to publish those counts. Severity and burden of viral 
hepatitis A, B and C disease are measured by information obtained from death certificates 
through the National Vital Statistics System (NVSS) (37).  
Surveillance activities also include the examination of other data sets which are not included in 
this report, such as the National Ambulatory Medical Care Survey (NAMCS) and the National 
Hospital Ambulatory Medical Care Survey (NHAMCS). Additional special studies, including the 
National Health and Nutrition Examination Survey (NHANES), which collects data from a 
nationally representative sample of about 5,000 non-institutionalized US residents each year, 
also are important in understanding the prevalence of chronic HCV infection (14; MM 
Denniston, manuscript submitted). Severity and burden of viral hepatitis A, B and C disease are 
measured by information obtained from death certificates through the National Vital Statistics 
System (NVSS) (37). 
National Notifiable Disease Surveillance System (NNDSS) 
Background 
Each week, state and territorial health departments report cases of acute, symptomatic viral 
hepatitis to CDC’s NNDSS. Since 1990, states have been electronically submitting individual 
case reports (absent of personal identifiers) to CDC. States’ participation in reporting nationally 
notifiable diseases, including viral hepatitis, is voluntary.  
National surveillance for viral hepatitis (including acute hepatitis A, hepatitis B, and hepatitis C; 
chronic hepatitis B; and chronic [past or present] hepatitis C) is based on case definitions 
developed and approved by the Council of State and Territorial Epidemiologists (CSTE) and 
CDC. In 2012, reported cases of acute and chronic viral hepatitis were required to meet the 




Death certificates are completed for all deaths registered in the United States. Information from 
death certificates is provided by funeral directors, attending physicians, medical examiners, and 
coroners, and certificates are filed in vital statistics offices within each state and the District of 
Columbia. Through a program called the National Vital Statistics System (NVSS) (36), 
information from death certificates is compiled by CDC’s National Center for Health Statistics 
(NCHS) to produce national multiple-cause-of-death (MCOD) data (38); causes of death are 
coded in accordance with the International Classification of Diseases, Tenth Revision (ICD-10) 
(39). MCOD data are used to determine the national burden of mortality associated with viral 
hepatitis infections and to describe the demographic characteristics of decedents. 
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A major study of these records from 1999 through 2007 showed that the annual number of deaths 
among HCV-infected persons exceeded deaths among HIV-infected persons beginning in 2007 
(16). 
Methods 
We analyzed national multiple-cause mortality data collected during 2007–2011 (the most recent 
data-years available) obtained from NCHS. The following case definitions were used to identify 
a death associated with hepatitis A, B, or C. 
Any death record with a report of: 
• Hepatitis A (ICD-10: B15), 
• Hepatitis B (ICD-10: B16, B17.0, B18.0, and B18.1), or 
• Hepatitis C (ICD-10: B17.1 and B18.2) listed as the underlying or one of the multiple 
(e.g., contributing) causes of death in the record axis. 
Demographic information on age, race, and sex were examined. Deaths were divided into six age 
categories: 0–34, 35–44, 45–54, 55–64, 65–74, and >75 years. Race categories for 2006-2009 
consisted of white (Hispanic and non-Hispanic), black (Hispanic and non-Hispanic), and non-
black, non-white (which included all other racial and ethnic groups). For 2010, race/ethnicity 
categories consisted of white non-Hispanic, black non-Hispanic, Hispanic, Asian/Pacific Islander 
(API) and American Indian/Alaska Native (AI/AN) to be consistent with those used by Division 
of Viral Hepatitis (DVH). To calculate national mortality rates, the number of deaths was divided 
by the total US Census population for each demographic subgroup. Rates on race, sex, and 
overall total were standardized to the age distribution of the US population in 2000 (40). Data 
were analyzed using SAS software, version 9.2 (SAS Institute; Cary, NC).  
Interpretation of Mortality Data 
• Differences in recording practices of death certificate information may cause 
misclassification of ICD-10 codes and demographic information. 
• Certain racial/ethnic populations likely are underrepresented in US Census data (the 
denominator for calculating rates), potentially causing overestimated rates for these 
populations. 
• Analyses do not adjust for deaths resulting from undiagnosed viral hepatitis infections.  
• Death records listing more than one type of viral hepatitis infection were counted once 
for each type of infection. For example, a death with ICD-10 codes for both hepatitis B 
and C virus infections is counted once as a hepatitis B death and once as a hepatitis C 
death. 
• The race category designated as “non-white/non-black” includes all other race groups 
(e.g., APIs, AI/ANs, and persons who are Hispanic). This lack of specificity limits race-
specific interpretation of mortality data prior to 2010.  
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Investigations of Acute Cases 
In 2012, CDC participated in 2 state-based investigations of outbreaks of viral hepatitis infection, 
one involving HBV and one involving HCV infection. Additional information may be found at 
the following link that summarizes known outbreaks 2008-2013. 
http://www.cdc.gov/hepatitis/Statistics/HealthcareOutbreakTable.htm 
Adjustments to Reported Cases 
CDC has reanalyzed the estimators (multipliers) traditionally used to convert reported cases to 
estimated (true) incidence of acute hepatitis A, B, and C in the United States. Briefly, this review 
and analysis has been of more recent data that allow better estimation of the numbers and 
percentages of acute viral hepatitis cases who have symptoms, seek medical care, and get 
reported to local, state and federal health authorities (1). A probabilistic model factored 
probabilities of symptoms (I), referral to care and treatment (II), and rates of reporting to local 
and state health department (III). This analysis indicated that reported cases represent an 
estimated one of 1.95 acute hepatitis A; one of 6.48 hepatitis B; and one of 12.30 hepatitis C 
cases1. Accordingly, these estimators are used in this Surveillance Summary. These estimates 
cannot be used to deduce trends by comparison with estimations obtained in previous years as 
earlier estimates were obtained from different (and unpublished) calculations; trends are best 
evaluated in reported cases, as in the increase in acute HCV in 2012 among nationally reported 
cases. 
1. Klevens RM, Liu SJ, Roberts H, Jiles RB, Holmberg SD. Estimating acute viral hepatitis 
infections from nationally reported cases. Am J Public Health, 2014;104 (3) 482-487.  
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HEPATITIS A 
Acute Hepatitis A.    
There were 1,562 reported cases of acute hepatitis A virus (HAV) infection in 2012, representing 
an estimated 3,050 cases.  
Case Definition 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms (e.g., nausea, 
anorexia, fever, malaise, and abdominal pain) and 2) jaundice, dark urine, or elevated serum 
alanine aminotransferase (ALT) >200 IU/L. 
Laboratory Criteria for Acute Hepatitis A 
• Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive. 
Acute Hepatitis A  
Historically, acute hepatitis A rates vary cyclically, with nationwide increases every 10-15 years. 
The last peak was in 1995; since that time, rates of hepatitis A have generally declined. In 2012, 
a total of 1,562 cases of acute hepatitis A were reported nationwide to CDC (Table 2.1). The 
overall incidence rate for 2012 was 0.5 cases per 100,000 population. No data were available for 
2012 from the District of Columbia. 
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Table 2.1 Reported cases of acute hepatitis A, by state ― United States, 2008–2012 
State 
2008 2009 2010 2011 2012 
Rate (No.) Rate (No.) Rate (No.) Rate (No.) Rate (No.) 
Alabama 0.3 (12) 0.3 (12) 0.2 (8) 0.2 (8) 0.4 (19) 
Alaska 0.7 (5) 0.3 (2) 0.7 (5) 0.6 (4) 0.1 (1) 
Arizona 1.8 (118) 1.0 (68) 1.0 (61) 1.2 (77) 1.4 (93) 
Arkansas 0.3 (10) 0.4 (12) 0.1 (2) 0.1 (3) 0.3 (8) 
California 1.2 (446) 0.7 (273) 0.6 (242) 0.5 (186) 0.5 (209) 
Colorado 0.7 (36) 1.0 (52) 0.7 (36) 0.4 (21) 0.5 (28) 
Connecticut 0.7 (26) 0.5 (18) 0.8 (29) 0.5 (18) 0.6 (23) 
Delaware 0.8 (7) 0.5 (4) 0.8 (7) 0.2 (2) 1.0 (9) 
District of Columbia U U 0.2 (1) 0.2 (1) U U U U 
Florida 0.8 (146) 0.9 (171) 0.7 (139) 0.5 (87) 0.5 (87) 
Georgia 0.6 (57) 0.5 (54) 0.4 (40) 0.3 (27) 0.5 (46) 
Hawaii 1.6 (20) 0.8 (11) 0.6 (8) 0.6 (8) 0.4 (5) 
Idaho 1.1 (17) 0.3 (5) 0.5 (8) 0.4 (6) 0.7 (11) 
Illinois 0.9 (112) 1.0 (126) 0.4 (48) 0.6 (73) 0.5 (67) 
Indiana 0.3 (20) 0.3 (17) 0.2 (12) 0.4 (24) 0.2 (11) 
Iowa 3.6 (109) 1.3 (38) 0.4 (11) 0.3 (8) 0.2 (7) 
Kansas 0.5 (15) 0.4 (12) 0.5 (14) 0.1 (4) 0.5 (15) 
Kentucky 0.7 (30) 0.3 (12) 0.6 (26) 0.2 (10) 0.6 (25) 
Louisiana 0.3 (12) 0.1 (6) 0.2 (11) 0.1 (5) 0.2 (7) 
Maine 1.4 (18) 0.1 (1) 0.5 (7) 0.5 (6) 0.7 (9) 
Maryland 0.8 (44) 0.8 (47) 0.4 (23) 0.4 (26) 0.5 (28) 
Massachusetts 0.9 (58) 1.1 (71) 0.7 (48) 0.6 (39) 0.6 (40) 
Michigan 1.2 (119) 0.7 (72) 0.7 (73) 0.7 (70) 1.0 (100) 
Minnesota 0.9 (49) 0.6 (29) 0.7 (37) 0.5 (27) 0.5 (29) 
Mississippi 0.2 (7) 0.3 (9) 0.1 (2) 0.2 (7) 0.4 (11) 
Missouri 0.6 (35) 0.4 (21) 0.4 (21) 0.2 (13) 0.3 (20) 
Montana 0.1 (1) 0.6 (6) 0.4 (4) 0.3 (3) 0.6 (6) 
Nebraska 2.3 (41) 1.2 (21) 0.8 (14) 0.3 (5) 0.9 (16) 
Nevada 0.5 (13) 0.6 (15) 0.5 (14) 0.2 (5) 0.4 (10) 
New Hampshire 0.9 (12) 0.5 (7) 0.2 (2) 0 (0) 0.5 (6) 
New Jersey 1.0 (86) 0.8 (71) 0.9 (76) 0.9 (79) 0.7 (60) 
New Mexico 0.9 (18) 0.4 (8) 0.2 (5) 0.3 (7) 0.5 (10) 
New York 0.9 (179) 0.7 (136) 0.8 (147) 0.6 (113) 0.6 (111) 
North Carolina 0.7 (63) 0.4 (41) 0.5 (48) 0.3 (31) 0.3 (34) 
North Dakota 0.3 (2) 0.3 (2) 0.6 (4) 0 (0) 0.3 (2) 
Ohio 0.4 (51) 0.3 (36) 0.4 (47) 0.3 (39) 0.3 (36) 
Oklahoma 0.4 (13) 0.2 (7) 0.2 (6) 0.3 (11) 0.3 (12) 
Oregon 0.7 (25) 0.5 (19) 0.4 (17) 0.3 (11) 0.2 (9) 
Pennsylvania 0.5 (68) 0.5 (68) 0.4 (53) 0.5 (60) 0.5 (62) 
Rhode Island 1.1 (12) 0.9 (9) 0.9 (9) 0.8 (8) 0.3 (3) 
South Carolina 0.4 (19) 1.4 (63) 0.6 (26) 0.2 (11) 0.1 (6) 
South Dakota 0.5 (4) 0.4 (3) 0.1 (1) 0.2 (2) 0 0 
Tennessee 0.5 (32) 0.2 (13) 0.2 (12) 0.4 (23) 0.4 (23) 
Texas 1.1 (259) 0.7 (184) 0.6 (139) 0.5 (138) 0.5 (134) 
Utah 0.5 (13) 0.3 (7) 0.4 (12) 0.3 (8) 0.1 (4) 
Vermont 0.3 (2) 0.3 (2) 0 0 1.0 (6) 0.3 (2) 
Virginia 0.7 (51) 0.5 (42) 0.6 (52) 0.4 (30) 0.6 (49) 
Washington 0.8 (51) 0.6 (42) 0.3 (21) 0.5 (31) 0.4 (29) 
West Virginia 0.3 (6) 0.3 (6) 0.8 (15) 0.4 (8) 0.4 (8) 
Wisconsin 0.6 (33) 0.6 (33) 0.4 (23) 0.1 (8) 0.4 (21) 
Wyoming 0.6 (3) 0.4 (2) 0.7 (4) 0.4 (2) 0.2 (1) 
Total  0.9 (2,585) 0.6 (1,987) 0.5 (1,670) 0.4 (1,398) 0.5 (1,562) 
*Rate per 100,000 population. †U=No data available for reporting.   






• The number of acute hepatitis A cases reported in the United States declined by 
approximately 53%, from 2,979 in 2007 to 1,562 in 2012. 
• The 1,562 acute hepatitis A cases represented an increase of 11% from 2011 to 2012.  
• Of the 50 states that reported hepatitis A cases in 2012, 25 states had rates below the 
national rate.  
• In 2012, the case rate ranged from no cases in South Dakota to 1.4 cases per 100,000 
population in Arizona. 
 
Table 2.2 Clinical characteristics of reported cases of acute hepatitis A* ― 
United States, 2012 
 
Clinical characteristic 
Availability of valid data† for clinical 
characteristic Cases with clinical characteristic§  
No. % No. % 
Jaundice 1,018 65.2 652 64 
Hospitalized for hepatitis A 1,022 65.4 468 45.8 
Died from hepatitis A 938 60.1 6 0.6 
*A total of 1,562 hepatitis A cases were reported during 2012.  
†Case reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with any other response were 
excluded.  
§Numbers and percentages represent only those case reports for which data regarding clinical characteristics were available; numbers likely are 
underestimates. 
 
• Of the 1,562 case reports of hepatitis A received during 2012, 65.2% included 
information about whether the patient had jaundice, 65.4% had information regarding 
hospitalization caused by hepatitis A, and 60.1% included information on hepatitis A-
associated death.  
• In 2012, of all case reports with information regarding clinical characteristics:  
o 64.0% indicated the patient had jaundice.  
o 45.8% indicated the patient was hospitalized as a result of hepatitis A. 
o 0.6% indicated the patient died from hepatitis A.  
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Table 2.3 Number and rate* of deaths with hepatitis A listed as a cause of death†, by 
demographic characteristic and year — United States, 2007–2011 
Demographic characteristic 
2007 2008 2009 2010 2011 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group (years) 
0–34 6 0.00 0 0.00 1 0.00 3 0.00 0 0.00 
35–44 3 0.01 1 0.00 1 0.00 7 0.02 1 0.00 
45–54 21 0.05 23 0.05 14 0.03 25 0.06 11 0.02 
55–64 20 0.06 24 0.07 22 0.06 34 0.09 16 0.04 
65–74 14 0.07 12 0.06 12 0.06 10 0.05 12 0.05 
>75 21 0.11 23 0.12 32 0.17 16 0.09 29 0.15 
Race§ 
White 70 0.03 63 0.02 68 0.02     
Black 14 0.04 13 0.04 13 0.04     
Non-White, Non-




Hispanic)       65 0.03 44 0.02 
Black, NH       15 0.04 10 0.03 
Hispanic       12 0.03 6 0.02 
Asian/ 
Pacific Islander       2 0.02 8 0.06 
American Indian/ 
Alaska Native       1 0.05 1 0.04 
Sex 
Male 61 0.04 51 0.03 50 0.03 73 0.05 37 0.02 
Female 24 0.01 32 0.02 32 0.02 22 0.01 32 0.02 
Overall 85 0.03 83 0.02 82 0.02 95 0.03 69 0.02 
* Rates for race, sex, and overall total are age-adjusted per 100,000 US standard population.  
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International Classification 
of Diseases, 10th Revision (ICD-10) codes B15 (hepatitis A).  
§Included white, non-Hispanic and white Hispanic.  
¶Included black, non-Hispanic and black Hispanic.  
**Included all other racial/ethnic groups.  
 
Source: CDC. National Vital Statistics System. 
 
• In 2011, the mortality rate of hepatitis A was 0.02 deaths per 100,000 population (n=69). 
From 2007 through 2011, mortality rates were higher among persons aged ≥45 years 
compared with persons younger than 45 years of age. 
• In 2011, the highest mortality rates for race/ethnicity and sex were observed among 
Asian/and Pacific Islanders (0.06 deaths per 100,000 population for each group). 
• Males and Females had the same rate of 0.02 deaths per 100,000 population.  


















Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• The number of reported cases of acute hepatitis A declined by 88%, from 13,397 in 2000 
to 1,562 in 2012. 
• Acute hepatitis A cases increased by 11% from 2011 to 2012. 



























   
   
   
   
   










Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• Rates of acute hepatitis A declined for all age groups from 2000-2012. 
• Rates were similar and low among persons in all age groups in 2012 (<1.0 case per 
100,000 population; range: 0.15–0.69). 
• In 2012, rates were highest for persons aged 20–29 years (0.69 cases per 100,000 
population); the lowest rates were among children aged < 9 years (0.15 cases per 100,000 
population). 


























   
   
   
   
   





Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• Since 2003, the rate of acute hepatitis A among males decreased and by 2012 was similar 
to that in females.  
• In 2012, the incidence rate was 0.5 cases per 100,000 population each for males and 
females. 






























   
   
   
   
   








Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• From 2000-2007, rates of hepatitis A among Hispanics were generally higher than those 
of other racial/ethnic populations.  
• In 2012, the rate of hepatitis A among Hispanics was 0.49 cases per 100,000 population, 
the lowest rate recorded for this group since 2000.   
• Although rates of acute hepatitis A among Asian/Pacific Islanders have continued to 
decline, from 2008-2012, this group had a higher rate of hepatitis A compared with other 
racial/ethnic groups; in 2012, the rate among Asian/Pacific Islanders was 0.59 per 
100,000 population. 





Source: National Notifiable Diseases Surveillance System (NNDSS)
* Includes case reports indicating the presence of at least one of the following risks 2–6 weeks prior to onset of acute, symptomatic hepatitis A: 1)  having 
traveled to hepatitis A-endemic regions of Mexico, South/Central America,  Africa,  Asia/South Pacific, or the Middle East; 2) having sexual/household or 
other contact with suspected/confirmed hepatitis A patient; 3) being a child/employee in day care center/nursery/preschool  or having had contact with 











• Of the 1,562 case reports of acute hepatitis A received by CDC during 2012, a total of 
568 (36%) cases did not include a response (i.e., a “yes” or “no” response to any of the 
questions about risk behaviors and exposures) to enable assessment of risk behaviors or 
exposures. 
• Of the 994 case reports that had a response: 
o 80% (n=793) indicated no risk behaviors/exposures for acute hepatitis A.  
o 20% (n=201) indicated at least one risk behavior/exposure for acute hepatitis A 
during the 2–6 weeks prior to onset of illness.  
o Of the 201 who indicated a risk, 92 (46%) indicated recent international travel. 
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*A total of 1,562 case reports of hepatitis A were received in 2012.  
† More than one risk behavior may be indicated on each case report.
§ No risk data reported.
¶A total of 769 hepatitis A cases were reported among males in 2012.























Figure 2.6a presents patient engagement in selected risk behaviors and exposures during the 
incubation period, 2–6 weeks prior to onset of symptoms: 
• Of the 713 case reports that had information about travel, 12.9% (n= 92) involved 
persons who had traveled outside the United States or Canada.  
• Of the 568 case reports that included information about injection-drug use, 2.3% (n=13) 
indicated use of these drugs. 
• Of the 65 case reports from males that included information about sexual 
preference/practices, 6.2% (n=4) indicated sex with another man. 
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*A total of 1,562 case reports with hepatitis A were received in 2012.  
† More than one risk exposure may be indicated on each case report. 
§ No risk data reported.


































Figure 2.6b presents patient engagement in selected risk behaviors and exposures during the 
incubation period, 2–6 weeks prior to onset of symptoms: 
• Of the 754 case reports that contained information about contact, 5.0% (n=38) involved 
persons who had sexual or household contact with a person confirmed or suspected of 
having hepatitis A. 
• Of the 873 case reports that included information about employment or attendance at a 
nursery, day-care center, or preschool, 1.6% (n=14) involved persons who worked at or 
attended a nursery, day-care center, or preschool. 
• Of the 792 case reports that included information about household contact with an 
employee of or a child attending a nursery, day-care center, or preschool, 4.3% (n=34) 
indicated such contact.  
• Of the 703 case reports that had information about linkage to an outbreak, 1.8% (n=13) 
indicated exposure that may have been linked to a common-source foodborne or 
waterborne outbreak. 
• Of the 754 case reports that included information about additional contact (i.e., other than 
household or sexual contact) with someone confirmed or suspected of having hepatitis A, 
3.1% (n=23) of persons reported such contact.  
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HEPATITIS B  
Acute Hepatitis B 
There were 2,895 reported cases of acute hepatitis B in 2012, representing an estimated 18,760 
acute cases.  
Case Definition 
Clinical Description 
An acute illness with 1) discrete onset of symptoms (e.g., nausea, anorexia, fever, malaise, and 
abdominal pain) and 2) jaundice or elevated serum alanine aminotransferase (ALT) >200 IU/L. 
Laboratory Criteria for Acute Hepatitis B 
• IgM antibody to hepatitis B core antigen (anti-HBc) positive OR hepatitis B surface 
antigen (HBsAg) positive 
AND  
• IgM anti-HAV negative (if performed). 
 
Acute Hepatitis B  
In 2012, a total of 2,895 cases of acute hepatitis B were reported nationwide to CDC (Table 3.1). 
The overall incidence rate for 2012 was 0.9 cases per 100,000 population. No data were available 
from the District of Columbia and Rhode Island for 2012.  
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Table 3.1. Reported cases of acute hepatitis B, by state ― United States, 2008-2012 
State 
2008 2009 2010 2011 2012 
Rate* (No.) Rate (No.) Rate (No.) Rate (No.) Rate (No.) 
Alabama 2.3 (109) 1.9 (89) 1.4 (68) 2.5 (119) 1.6 (79) 
Alaska 1.5 (10) 0.6 (4) 0.7 (5) 0.4 (3) 0.1 (1) 
Arizona 1.2 (80) 0.6 (42) 0.4 (26) 0.2 (14) 0.2 (14) 
Arkansas 2.3 (67) 2.2 (65) 2.3 (66) 1.9 (57) 2.5 (74) 
California 0.8 (303) 0.7 (258) 0.7 (252) 0.4 (157) 0.4 (136) 
Colorado 0.7 (33) 0.5 (27) 0.9 (46) 0.4 (23) 0.5 (24) 
Connecticut 0.9 (30) 0.5 (16) 0.6 (22) 0.5 (19) 0.4 (15) 
Delaware U†  U U U U U U U 1.2 (11) 
District of Columbia U U 1.7 (10) 0.5 (3) U U U U 
Florida 1.9 (344) 1.6 (299) 1.6 (297) 1.1 (213) 1.3 (247) 
Georgia 1.9 (187) 1.5 (144) 1.7 (165) 1.4 (142) 1.1 (109) 
Hawaii 0.5 (7) 0.5 (6) 0.4 (6) 0.4 (6) 0.4 (5) 
Idaho 0.8 (12) 0.7 (11) 0.4 (6) 0.1 (2) 0.3 (5) 
Illinois 1.4 (184) 0.9 (118) 1.1 (135) 0.7 (85) 0.7 (86) 
Indiana 1.0 (67) 1.2 (74) 1.2 (75) 1.1 (70) 1.4 (90) 
Iowa 0.8 (24) 1.2 (37) 0.5 (15) 0.5 (15) 0.4 (13) 
Kansas 0.3 (9) 0.2 (6) 0.4 (11) 0.5 (15) 0.3 (9) 
Kentucky 2.4 (101) 2.1 (90) 3.1 (136) 3.5 (151) 4.1 (180) 
Louisiana 2.1 (94) 1.6 (73) 1.2 (55) 1.4 (62) 1.0 (44) 
Maine 1.1 (15) 1.1 (15) 1.0 (13) 0.6 (8) 0.7 (9) 
Maryland 1.5 (85) 1.3 (72) 1.2 (67) 1.1 (62) 0.9 (52) 
Massachusetts 0.3 (21) 0.3 (17) 0.2 (13) 1.0 (67) 1.1 (75) 
Michigan 1.5 (149) 1.3 (132) 1.2 (122) 0.9 (91) 0.8 (81) 
Minnesota 0.5 (25) 0.7 (38) 0.4 (23) 0.4 (20) 0.3 (17) 
Mississippi 1.7 (50) 1.1 (33) 1.1 (33) 1.9 (57) 2.6 (78) 
Missouri 0.6 (38) 0.8 (47) 1.1 (67) 1.0 (60) 0.8 (48) 
Montana 0.2 (2) 0.1 (1) 0 (0) 0 (0) 0.2 (2) 
Nebraska 0.5 (9) 1.2 (22) 0.7 (12) 0.7 (12) 0.5 (10) 
Nevada 1.6 (43) 1.3 (34) 1.5 (41) 1.1 (29) 1.0 (28) 
New Hampshire 0.6 (8) 0.5 (6) 0.4 (5) 0.2 (3) 0.3 (4) 
New Jersey 1.4 (118) 1.1 (93) 0.9 (77) 0.8 (73) 0.8 (70) 
New Mexico 0.6 (12) 0.4 (8) 0.2 (5) 0.5 (10) 0.1 (3) 
New York 0.9 (173) 0.7 (129) 0.7 (139) 0.7 (134) 0.6 (113) 
North Carolina 0.9 (81) 1.1 (104) 1.2 (113) 1.1 (109) 0.7 (73) 
North Dakota 0.3 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
Ohio 1.0 (118) 0.8 (88) 0.8 (95) 0.8 (90) 1.5 (178) 
Oklahoma 3.5 (129) 3.3 (122) 3.1 (115) 2.6 (100) 2.1 (79) 
Oregon 1.1 (41) 1.2 (44) 1.1 (42) 0.8 (32) 0.6 (25) 
Pennsylvania 1.2 (157) 0.8 (106) 0.6 (72) 0.7 (84) 0.5 (63) 
Rhode Island U U U U U U U U U U 
South Carolina 1.6 (71) 1.2 (56) 1.3 (59) 0.8 (39) 0.8 (37) 
South Dakota 0 (0) 0.5 (4) 0.2 (2) 0.2 (2) 0.2 (2) 
Tennessee 2.4 (149) 2.2 (136) 2.4 (150) 3.0 (192) 3.7 (240) 
Texas 2.3 (562) 1.7 (420) 1.6 (394) 0.8 (204) 0.7 (170) 
Utah 0.5 (14) 0.2 (5) 0.3 (8) 0.4 (10) 0.5 (13) 
Vermont 0.5 (3) 0 (0) 0.3 (2) 0 (0) 0.3 (2) 
Virginia 1.7 (130) 1.4 (110) 1.2 (97) 1.0 (84) 1.0 (84) 
Washington 0.9 (56) 0.7 (48) 0.7 (50) 0.5 (35) 0.5 (34) 
West Virginia 4.6 (83) 4.6 (84) 4.7 (88) 6.1 (113) 7.6 (141) 
Wisconsin 0.3 (18) 0.4 (24) 0.9 (54) 0.3 (17) 0.4 (22) 
Wyoming 1.1 (6) 0.7 (4) 0.5 (3) 0 (0) 0 (0) 
Total 1.3 (4,029) 1.1 (3,371) 1.1 (3,350) 0.9 (2,890) 0.9 (2,895) 
*Rate per 100,000 population.  
†U=No data available for reporting.   
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• The number of acute cases of hepatitis B decreased by 28% overall during 2008–2012, 
from 4,029 cases to 2,895 cases; increases in Arkansas, Indiana, Kentucky, 
Massachusetts, Mississippi, Missouri, Ohio, Tennessee and West Virginia occurred 
during this time period. 
• Of the 49 states that reported acute hepatitis B cases in 2012, 30 states had rates below 
the national rate of 0.9 per 100,000 population.  
• Rates of acute hepatitis B in 2012 ranged from no cases reported in North Dakota and 





Table 3.2. Clinical characteristics of reported cases of acute hepatitis B* ―  
United States, 2012 
 
Clinical characteristic 
Availability of valid data† for clinical 
characteristic Cases with clinical characteristic§  
No. % No. % 
Jaundice 2,072 71.6 1,565 75.5 
Hospitalized for hepatitis B 1,997 69.0 1,198 60.0 
Died from hepatitis B 1,846 63.8 20 1.1 
*A total of 2,895 hepatitis B cases were reported during 2012.  
†Case reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with any other response were 
excluded.  
§Numbers and percentages represent only those case reports for which data regarding clinical characteristics were available; numbers likely are 
underestimated 
 
• Of the 2,895 case reports of acute hepatitis B received in 2012, 69.0% included 
information regarding whether the patient had jaundice, 71.6% had information regarding 
hospitalization caused by hepatitis B, and 63.8% included information on hepatitis B-
associated deaths. 
• In 2012, of all case reports with information about clinical characteristics:  
o 75.5% indicated the patient had jaundice.  
o 60.0% indicated the patient was hospitalized as a result of hepatitis B.  
o 1.1% indicated the patient died from hepatitis B.  
  




















Source: National Notifiable Diseases Surveillance System (NNDSS)
 
• The number of reported cases of acute hepatitis B decreased 64%, from 8,036 in 2000 to 
2,895 in 2012. 
  


























   
   
   
   
   









Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• Declines in reported cases of hepatitis B were observed in all age groups. 
• In 2012, the highest rates were among persons aged 30–39 years (2.17 cases/100,000 
population), and the lowest were among adolescents and children aged <19 years (0.03 
cases/100,000 population). 




























   
   
   
   
   









• While the incidence rate of acute hepatitis B remained higher for males than for females, 
the gap has narrowed from 2002-2012.  
• Incidence rates of acute hepatitis B decreased for both males and females from 2000 
through 2012. 
• In 2012, the rate for males was approximately 1.7 times higher than that for females (1.17 
cases and 0.68 cases per 100,000 population, respectively).  






























   
   
   
   
   












• The absolute number and rate of hepatitis B cases has declined generally for all 
race/ethnicity categories from 2000-2012.   
• With the exception of white, non-Hispanics, declines were observed among all 
racial/ethnic groups ranging from 75%-90% during 2000-2012.   
• White, non-Hispanic cases had the lowest rates in 2000, but have declined only 44% over 
the 12-year period compared with other racial/ethnic groups. In 2012, the hepatitis B rate 
among white, non-Hispanics was 0.8 cases per 100,000 population.   
• In 2012, the rate of acute hepatitis B was lowest for Asian/Pacific Islanders and 
Hispanics (0.4 cases per 100,000 population for each group) and highest for black, non-
Hispanics (1.1 cases per 100,000 population). 
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Source: National Notifiable Diseases Surveillance System (NNDSS)
* Includes case reports indicating the presence of at least one of the following risks 6 weeks to 6 months prior to onset of acute, symptomatic hepatitis B:  
1) using injection drugs; 2) having sexual contact with suspected/confirmed hepatitis B patient; 3) being a man who has sex with men; 4) having multiple 
sex partners concurrently; 5) having household contact with suspected/confirmed hepatitis B patient; 6) occupational exposure to blood; 7) being a 













• Of the 2,895 case reports of acute hepatitis B received by CDC during 2012, a total of 
1,205 (42%) did not include a response (i.e., a “yes” or “no” response to any of the 
questions about risk behaviors and exposures) to enable assessment of risk behaviors or 
exposures.  
• Of the 1,690 case reports that had risk behavior/exposure information:  
o 60.6% (n=1,024) indicated no risk behaviors/exposures for hepatitis B. 
o 39.4% (n=666) indicated at least one risk behavior/exposure for hepatitis B during 
the 6 weeks to 6 months prior to illness onset. 
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*A total of 2,895 case reports of hepatitis B were received in 2012.
† More than one risk behavior may be indicated on each case report.
§ No risk data reported.
¶A total of 1,803 hepatitis B cases were reported among males in 2012..

































Figure 3.6a presents patient engagement in selected risk behaviors and exposures during the 
incubation period, 6 weeks to 6 months prior to onset of symptoms.  
• Of the 1,345 case reports that had information about injection-drug use, 20.8% (n=280) 
noted use of these drugs. 
• Of the 666 who could specify a risk, 280 (42%) indicated injection drug use, and 194 
(29%) indicated multiple recent sex partners.  
• Of the 912 case reports that had information about sexual contact, 5.0% (n=46) indicated 
sexual contact with a person with confirmed or suspected hepatitis B infection. 
• Of the 142 case reports from males that included information about sexual 
preference/practices, 25.4% (n=36) indicated sex with another man.  
• Of the 661 case reports that had information about number of sex partners, 29.3% 
(n=194) were among persons with ≥2 sex partners. 
• Of the 912 case reports that had information about household contact, 1.1% (n=10) 
indicated household contact with someone with confirmed or suspected hepatitis B 
infection. 
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*A total of 2,895 case reports of hepatitis B were received in 2012.  
†More than one risk exposure may be indicated on each case report.
§Risk data not reported.




























Figure 3.6b presents patient engagement in selected risk behaviors and exposures during the 
incubation period, 6 weeks to 6 months prior to onset of symptoms.  
• Of the 1,484 case reports that contained information about occupational exposures, 0.7% 
(n=11) indicated employment in a medical, dental, or other field involving contact with 
human blood. 
• Of the 1,177 case reports that included information about receipt of dialysis or kidney 
transplant, 0.2% (n=2) reported receipt of dialysis or a kidney transplant. 
• Of the 1,378 case reports that had information about receipt of blood transfusion, 0.4% 
(n=5) noted receipt of a blood transfusion. 
• Of the 1,376 case reports that had information about surgery they had received, 10.8% 
(n=148) reported having had surgery. 
• Of the 1,306 case reports that had information about needle sticks, 5.1% (n=67) reported 
an accidental needle stick/puncture. 
  
Surveillance for Viral Hepatitis — United States, 2012 
35 
Chronic Hepatitis B 
Case Definition 
Clinical Description 
No symptoms are required. Persons with chronic hepatitis B virus (HBV) infection may have no 
evidence of liver disease or may have a spectrum of disease ranging from chronic hepatitis to 
cirrhosis or liver cancer.  
Laboratory Criteria 
• IgM anti-HBc negative 
AND 
• a positive result on one of the following tests: HBsAg, hepatitis B e antigen (HBeAg) or 
HBV DNA  
OR 
• Two positive tests for HBsAg, HBV DNA, or HBeAg when tests are performed at least 6 
months apart (any combination of these tests performed 6 months apart is acceptable).  
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Table 3.3. Number of laboratory-confirmed, chronic hepatitis B* case reports — National 
Notifiable Diseases Surveillance System (NNDSS), 2012 
 
Jurisdiction^ No. chronic hepatitis B case reports submitted 
Arizona  892 
Colorado  458 
Connecticut § 562 
Delaware  149 
Illinois  1,714 
Kansas  112 
Louisiana  603 
Maine  105 
Massachusetts  1,750 
Michigan  1,416 
Montana  25 
New York § 1,611 
New York City  12,002 
North Carolina  888 
Pennsylvania § 1,952 
South Carolina  463 
South Dakota  51 
Vermont  28 
West Virginia  163 
Wyoming § 6 
Total 24,950 
* For case-definition, see 
http://wwwn.cdc.gov/nndss/script/ConditionList.aspx?Type=0&Yr=2012 
†Reports may not reflect unique cases. 
§Includes probable and confirmed case reports.  
^Jurisdictions that gave permission to report their chronic HBV cases 
 
• In 2012, a total of 44 states submitted 40,599 reports of chronic hepatitis B to CDC. 
• Twenty jurisdictions agreed to publication of their NNDSS data for this report, representing 
61.5% (n=24,950) of all reports of chronic hepatitis B received by CDC. 
• In 2012, the greatest number of reports was received from New York (n=12,002), 
representing 48.1% of published reports. 
• The range in the number of reports of chronic hepatitis B which contained only confirmed 
reports was 6 received from Wyoming to 12,002 received from New York.  
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Table 3.4. Number and rate* of deaths with hepatitis B listed as a cause of death, by 
demographic characteristic and year – United States, 2007-2011 
Demographic Characteristic 
2007 2008 2009 2010 2011 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years) 
0–34 62 0.04 44 0.03 39 0.03 48 0.03 41 0.03 
35–44 184 0.43 154 0.36 143 0.34 142 0.35 143 0.35 
45–54 532 1.21 533 1.20 469 1.05 448 1.00 421 0.94 
55–64 546 1.67 523 1.55 547 1.57 610 1.67 645 1.69 
65–74 266 1.37 271 1.35 254 1.22 296 1.36 285 1.27 
>75 225 1.21 263 1.40 245 1.30 248 1.34 269 1.42 
Race§ 
White 1,081 0.40 1,093 0.40 978 0.35         
Black 359 1.03 327 0.92 320 0.87         
Non-White, 




Hispanic)             856 0.34 832 0.32 
Black, NH             356 0.94 373 0.98 
Hispanic             136 0.43 161 0.48 
Asian/ 




            17 0.73 9 0.38 
Sex 
Male 1,345 0.88 1,315 0.85 1,267 0.80 1,316 0.81 1,321 0.80 
Female 470 0.28 473 0.27 430 0.24 476 0.27 483 0.26 
Overall 1,815 0.56 1,788 0.54 1,697 0.51 1,792 0.52 1,804 0.52 
 * Rates for race, sex, and overall total are age-adjusted per 100,000 US standard population.  
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International 
Classification of Diseases, 10th Revision (ICD-10) codes B16, B17.0, B18.0, and B18.1(hepatitis B).  
§Included white, non-Hispanic and white Hispanic.  
¶Included black, non-Hispanic and black Hispanic.  
**Included all other racial/ethnic groups.  
 
Source: CDC. National Vital Statistics System. 
 
• In 2011, the mortality rate for hepatitis B was 0.5 deaths per 100,000 population (n=1,804). 
• In 2011, the highest mortality rates by age, race/ethnicity and sex were observed among 
persons aged 55–64 years (1.7 deaths per 100,000 population), Asians and Pacific Islanders 
(2.7 deaths per 100,000 population), and males (0.8 deaths per 100,000 population) 
respectively. 
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HEPATITIS C  
Acute Hepatitis C 
There were 1,778 reported cases of acute HCV in 2012—a 75% increase compared with the 
number of cases reported in 2010.  This number represents an estimated 21,870 acute cases.  
Case Definition 
Clinical Description 
An acute illness with 1) discrete onset of symptoms (e.g., nausea, anorexia, fever, malaise, and 
abdominal pain) and 2) either jaundice/dark urine or serum alanine aminotransferase (ALT) >400 
IU/L. 
Laboratory Criteria for Acute Hepatitis C 
• IgM anti-HAV negative and IgM anti-HBc negative 
AND 
• One or more of the following three criteria:  
o Antibody to hepatitis C virus (anti-HCV) screening-test positive, with a signal-to-
cut-off ratio predictive of a true positive for the particular assay as defined by 
CDC (signal to cut-off ratios available at 
http:/www.cdc.gov/hepatitis/HCV/LabTesting.htm)  
o OR 
o Hepatitis C Virus Recombinant Immunoblot Assay (HCV RIBA) positive 
o OR 
o Nucleic Acid Test (NAT) for HCV RNA positive (including genotype). 
Acute Hepatitis C  
In 2012, a total of 41 states submitted 1,778 reports of acute hepatitis C to CDC (Table 4.1). The 
overall incidence rate for 2012 was 0.6 cases per 100,000 population, an increase from 0.3 cases 
per 100,000 population during 2006-2010. Data for 2012 were unavailable from Alaska, 
Arizona, Delaware, the District of Columbia, Hawaii, Mississippi, New Hampshire, Rhode 
Island, South Dakota ,and Wyoming. 
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Table 4.1. Reported cases of acute hepatitis C, by state ― United States, 2008–2012 
State  
2008 2009 2010 2011 2012 
Rate* (No.) Rate (No.) Rate (No.) Rate (No.) Rate (No.) 
Alabama 0.3 (13) 0.2 (10) 0.1 (7) 0.5 (23) 0.5 (24) 
Alaska U†  U U U U U U U U U 
Arizona U U U U U U U U U U 
Arkansas 0 (1) 0.1 (2) 0 (1) 0 (0) 0.2 (5) 
California 0.1 (30) 0.1 (43) 0.1 (32) 0.1 (48) 0.2 (63) 
Colorado 0.3 (14) 0.6 (28) 0.4 (20) 0.5 (28) 0.8 (42) 
Connecticut 0.5 (19) 1.5 (53) 1.0 (37) 1.3 (47) 0.9 (34) 
Delaware U U U U U U U U U U 
District of Columbia U U 0.2 (1) 0.3 (2) U U U U 
Florida 0.2 (32) 0.3 (53) 0.3 (56) 0.3 (64) 0.6 (107) 
Georgia 0.2 (16) 0.3 (31) 0.3 (32) 0.5 (53) 0.8 (82) 
Hawaii U U U U U U U U U U 
Idaho 0.2 (3) 0.5 (7) 0.7 (11) 0.8 (12) 0.7 (11) 
Illinois 0.1 (10) 0 (6) 0 (1) 0 (6) 0.2 (26) 
Indiana 0.2 (13) 0.3 (22) 0.4 (27) 1.3 (84) 1.7 (110) 
Iowa 0 (0) 0.4 (11) 0 0 0 (0) 0.1 (3) 
Kansas 0 (1) 0 (1) 0.1 (2) 0.3 (8) 0.6 (16) 
Kentucky 1.6 (68) 1.5 (64) 2.5 (109) 3.2 (142) 4.1 (178) 
Louisiana 0.2 (9) 0.2 (9) 0.1 (4) 0.2 (7) 0.2 (11) 
Maine 0.2 (3) 0.2 (2) 0.2 (2) 0.9 (12) 0.6 (8) 
Maryland 0.4 (22) 0.4 (23) 0.4 (24) 0.6 (35) 0.7 (39) 
Massachusetts 0.2 (13) 0.2 (10) 0.2 (13) 0.3 (23) 0.6 (37) 
Michigan 1.3 (129) 0.4 (35) 0.5 (45) 0.3 (32) 0.8 (76) 
Minnesota 0.4 (22) 0.3 (15) 0.3 (16) 0.3 (17) 0.6 (32) 
Mississippi U U U U U U U U U U 
Missouri 0 (2) 0 (0) 0.1 (6) 0.1 (8) 0.1 (4) 
Montana 0.6 (6) 0.1 (1) 0.4 (4) 0.9 (9) 0.9 (9) 
Nebraska 0.1 (2) 0.2 (3) 0.1 (2) 0.1 (2) 0.2 (3) 
Nevada 0.8 (22) 0.2 (5) 0.3 (7) 0.4 (10) 0.4 (12) 
New Hampshire U U U U U U U U U U 
New Jersey 0.7 (61) 0.1 (7) 0.3 (28) 0.6 (53) 0.8 (71) 
New Mexico 0.3 (5) 0.3 (6) 0.7 (14) 0.7 (14) 1.0 (21) 
New York 0.2 (43) 0.3 (53) 0.3 (50) 0.3 (52) 0.5 (93) 
North Carolina 0.5 (46) 0.3 (24) 0.4 (39) 0.6 (60) 0.6 (63) 
North Dakota 0 (0) 0.3 (2) 0 (0) 0 (0) 0 (0) 
Ohio 0.3 (40) 0.2 (26) 0.1 (10) 0.1 (6) 0.1 (7) 
Oklahoma 0.5 (20) 0.7 (27) 1.1 (41) 1.4 (53) 2.1 (80) 
Oregon 0.6 (23) 0.5 (19) 0.5 (19) 0.5 (20) 0.9 (37) 
Pennsylvania 0.2 (27) 0.3 (39) 0.2 (26) 0.3 (35) 0.5 (66) 
Rhode Island U U U U U U U U U U 
South Carolina 0.1 (4) 0 (1) 0 (1) 0 (1) 0.0 (1) 
South Dakota U U U U U U U U U U 
Tennessee 0.4 (28) 0.5 (33) 0.7 (46) 1.3 (83) 2.0 (129) 
Texas 0.2 (59) 0.1 (36) 0.1 (35) 0.1 (37) 0.2 (44) 
Utah 0.4 (12) 0.2 (6) 0.4 (10) 0.4 (10) 0.6 (17) 
Vermont 0.2 (1) 0.2 (1) 0.3 (2) 1.0 (6) 1.0 (6) 
Virginia 0.1 (8) 0.1 (10) 0.2 (13) 0.3 (25) 0.9 (76) 
Washington 0.4 (25) 0.3 (22) 0.4 (25) 0.6 (41) 0.8 (54) 
West Virginia 1.2 (22) 1.7 (31) 1.1 (21) 2.5 (46) 3.0 (55) 
Wisconsin 0.1 (3) 0.1 (3) 0.2 (10) 0.3 (15) 0.5 (26) 
Wyoming 0 (0) 0 (0) 0 (0) 0.4 (2) U U 
Total 0.3 (877) 0.3 (781) 0.3 (850) 0.4 (1,229) 0.6 (1,778) 
*Rate per 100,000 population.      †U=No data available for reporting.   
Division of Viral Hepatitis, CDC 
40 
 
• The number of acute cases of hepatitis C reported in the United States increased 45%, 
from 1,229 in 2011 to 1,778 in 2012. 
• The national rate of acute cases of hepatitis C remained stable, at 0.3 cases per 100,000 
population from 2008 through 2010, but increased to 0.4 cases per 100,000 population in 
2011, and to 0.6 cases per 100,000 population in 2012. 
• Of the 41 states that submitted reports of acute hepatitis C in 2012, 15 states had rates 
below the national rate of 0.6 cases per 100,000 population.  
• Rates of acute hepatitis C ranged from no cases reported in North Carolina to 4.1 cases 
per 100,000 population in Kentucky. 
• In 35 states, the number of reported acute hepatitis C cases increased from 2008 to 2012.  
• Three Appalachian states — Kentucky, Tennessee, and West Virginia — accounted for 




Table 4.2 Clinical characteristics of reported cases of acute, hepatitis C* ― 
United States, 2012 
Clinical characteristic 
Availability of valid data† for 
clinical characteristic 
Cases with clinical 
characteristic§ 
No. % No. % 
Jaundice 1,278 71.9 870 68.1 
Hospitalized for hepatitis C 1,216 68.4 675 55.5 
Died from hepatitis C 1,123 63.2 6 0.5 
*A total of 1,778 hepatitis C cases were reported during 2012.  
†Case reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports 
with any other response were excluded.  
§Numbers and percentages represent only those case reports for which data regarding clinical characteristics 
were available; numbers likely are underestimates. 
• Of the 1,778 case reports of acute hepatitis C received in 2012, 70.9% included 
information regarding whether the patient had jaundice, 68.4% had information regarding 
hospitalization caused by hepatitis C, and 63.2% included information on hepatitis C-
associated deaths. (Note: more severe cases are likely to be ascertained and reported.) 
• In 2012, of all case reports with information regarding clinical characteristics:  
o 68.1% indicated the patient had jaundice.  
o 55.5% indicated the patient was hospitalized as a result of hepatitis C. 
o  0.5% indicated the patient died from hepatitis C. 
  


















Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• The number of reported cases of acute hepatitis C declined rapidly until 2003 and 
remained steady until 2010.  However, from 2010 to 2011 there was a 45% increase in 
the number of reported hepatitis C (from 850 to 1,229 cases) and another 45% increase 
from 2011 to 2012 (from 1,229 to 1,778 cases), representing a 75% increase from 2010-
2012.  


























   
   
   
   
   









Source: National Notifiable Diseases Surveillance System (NNDSS)
 
  
• Prior to 2002, incidence rates for acute hepatitis C decreased for all age groups (with the 
exception of the 0–19 year age group); rates remained fairly constant for all age groups 
from 2002 through 2010. 
• In 2012, the rate of acute hepatitis C increased in every age group when compared with 
2010 and 2011, with the largest increases among persons aged 0-19 years (from 0.05 to 
0.11 cases per 100,000 population) and 20–29 years (from 0.75 to 1.73 cases per 100,000 
population).  When comparing the 2012 hepatitis C rates of all age groups, persons aged 
20–29 years had the highest rate (1.73 cases per 100,000 population) and persons aged 
≥60 years had the lowest rate (0.10 cases per 100,000 population). 




























   
   
   
   
   









• Incidence rates of acute hepatitis C decreased dramatically for both males and females 
from 2000-2003 and remained fairly constant from 2004-2010. 
• Since 2010, rates for both males and females have increased and in 2012, rates among 
males and females were 0.7 and 0.5 cases per 100,000 population, respectively.  

























   
   
   
   
   












• Rates for acute hepatitis C decreased for all racial/ethnic populations through 2003. 
• From 2011-2012, acute hepatitis C rates increased 86.2% among American 
Indians/Alaska natives, 36.2% among white, non-Hispanics, and 23.5% among 
Hispanics. 
• The 2012 acute hepatitis C rates for Asian/Pacific Islanders, black, non-Hispanics, 
Hispanics, white, non-Hispanic, and American Indian/Alaska Natives were 0.1, 0.2, 0.2, 
0.6 and 2.0, respectively. 
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*Includes case reports indicating the presence of at least one of the following risks 6 weeks to 6 months prior to onset of acute, symptomatic 
hepatitis C:  1) using injection drugs; 2) having sexual contact with suspected/confirmed hepatitis C patient; 3) being a man who has sex with 
men; 4) having multiple sex partners concurrently; 5) having household contact with suspected/confirmed hepatitis C patient; 6) having had 
occupational exposure to blood; 7) being a hemodialysis patient; 8) having received a blood transfusion; 9)  having sustained a 
percutaneous injury; and 10) having undergone surgery.
 
  
• Of the 1,778 case reports of acute hepatitis C received by CDC during 2012, 728 (40.9%) 
did not include a response (i.e., a “yes” or “no” response to any of the questions about 
risk behaviors and exposures) to enable assessment of risk behaviors or exposures. 
• Of 1,050 case reports that had risk factor/exposure information: 
o 368 (35%) indicated no risk behaviors/exposures for hepatitis C virus infection. 
o 682 (65%) indicated at least one risk behavior/exposure in the 2 weeks to 6 
months prior to illness onset. 
• Of the 682 who reported risk information:  
o 513 (75%) indicated injection drug use risk (Figure 4.6a). 
o 86 (13%) indicated recent surgery. 
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*A total of 1,778 case reports of hepatitis C were received in 2012.  
† More than one risk behavior may be indicated on each case report.
§Risk data not reported. 
¶A total of 955 hepatitis C cases were reported among males in 2012.
































Figure 4.6a presents patient engagement in selected risk behaviors and exposures during the 
incubation period, 2 weeks to 6 months prior to onset of symptoms. 
• IDU is the most prevalent risk behavior identified. 
• Of the 859 case reports who answered “yes” or “no” to recent injection drug use, 513 
(60%) said “yes” to the question.  Of the 221 case reports from males that included 
information about sexual preferences/practices, 7.7% (n=17) indicated sex with another 
man.  
• Of the 122 case reports that had information about sexual contact, 14.8% (n=18) involved 
persons reporting sexual contact with a person with confirmed or suspected HCV 
infection. 
• Of the 629 case reports that had information about number of sex partners, 29.7% 
(n=187) involved persons with ≥2 sex partners. 
• Of the 122 case reports that had information about household contact, 6.6% (n=8) 
indicated household contact with someone with confirmed or suspected HCV infection. 
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*A total of 1,778 case reports of hepatitis C were received in 2012.  
†More than one risk exposure may be indicated on each case report.
§Risk data not reported.
























Figure 4.6b presents patient engagement in selected exposures during the incubation period, 
2 weeks to 6 months prior to onset of symptoms. 
• Of the 804 case reports that contained information about occupational exposures, 1.7% 
(n=14) involved persons employed in a medical, dental, or other field involving contact 
with human blood. 
• Of the 718 case reports that had information about receipt of dialysis or a kidney 
transplant, 0.6% (n=4) indicated patient receipt of dialysis or a kidney transplant. 
• Of the 671 case reports that had information about surgery, 12.8% (n=86) were among 
persons who had undergone surgery. 
• Of the 711 case reports that included information about needle sticks, 7.3% (n=52) 
indicated accidental needle stick/puncture.  
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Hepatitis C, Past or Present 
The current case definition for hepatitis C cases, other than acute cases, requires as little as a 
single positive anti-HCV test and that the case does not meet the case definition for acute 
infection. Because no single current anti-HCV test can distinguish current active infections 
(present) from resolved infections (past), these cases are reported in a single category, hepatitis 




No symptoms are required. Most HCV-infected persons are asymptomatic; however, many have 
mild-to-severe chronic liver disease. 
Laboratory Criteria 
One or more of the following three criteria (except in persons less than 18 months of age, for 
whom only criteria 3 would meet the case classification criteria):  
• Antibodies to hepatitis C virus (anti-HCV) screening-test-positive with a signal to cut-off 
ratio predictive of a true positive as determined for the particular assay as defined by 
CDC. (URL for the signal to cut-off ratios: 
http://www.cdc.gov/hepatitis/HCV/LabTesting.htm), OR  
• Hepatitis C virus recombinant immunoblot assay (HCV RIBA) positive, OR  
• Nucleic acid test (NAT) for HCV RNA positive (including qualitative, quantitative or 





A case that does not meet the case definition for acute hepatitis C, is anti-HCV positive (repeat 
reactive) by EIA, and has alanine aminotransferase (ALT or SGPT) values above the upper limit 
of normal, but the anti-HCV EIA result has not been verified by an additional more specific 
assay or the signal to cut-off ratio is unknown.  
 
Confirmed 
A case that is laboratory confirmed and does not meet the case definition for acute hepatitis C.  
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Table 4.3 Number of laboratory confirmed, hepatitis C (past or present)* case 
reports† — National Notifiable Diseases Surveillance System (NNDSS), 2012 
 
  










New York 6,791 
New York City 7,598 
Pennsylvania 9,747 
South Carolina 3,672 




* For case-definition, see 
http://wwwn.cdc.gov/nndss/script/ConditionList.aspx?Type=0&Yr=2012. 
†Reports may not reflect unique cases. 
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• In 2012, a total of 145,762 reports of chronic hepatitis C (past or present) infection were 
submitted to CDC by 44 states. 
• Sixteen jurisdictions agreed to publication of their NNDSS data for this report, 
representing 44.1% (n=64,370) of all reports of chronic hepatitis C received by CDC in 
2012. 
• Of the 16 states, the greatest number of reports was received from Pennsylvania 
(n=9,747); the least number of reports was received from Wyoming (n=521). 
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Table 4.4. Number and rate* of deaths with hepatitis C listed as a cause of 
death†, by demographic characteristic and year — United States, 2007–2011 
Demographic 
characteristic 
2007 2008 2009 2010 2011 




0–34 131 0.09 124 0.09 116 0.08 117 0.08 128 0.09 
35–44 999 2.32 878 2.07 828 1.99 712 1.73 696 1.71 
45–54 5,937 13.53 5,758 12.98 5,469 12.26 5,171 11.49 5,073 11.34 
55–64 5,145 15.72 5,967 17.71 6,683 19.21 7,431 20.37 8,330 21.89 
65–74 1,621 8.37 1,709 8.49 1,824 8.77 1,901 8.75 2,136 9.50 
>75 1,273 6.85 1,332 7.11 1,333 7.10 1,293 6.97 1,357 7.18 
Race¶ 
White 11,798 4.31 12,261 4.37 12,682 4.43         












            10575 4.03 11196 4.19 
Black, NH             2981 7.72 3167 7.89 









            248 9.90 275 10.61 
Sex 
Male 10,561 6.64 11,116 6.82 11,517 6.91 11,781 6.81 12,651 7.11 
Female 4,545 2.65 4,652 2.65 4,736 2.65 4,846 2.63 5,070 2.70 
Overall 15,106 4.58 15,768 4.66 16,253 4.70 16,627 4.65 17,721 4.82 
 * Rates for race, sex, and overall total are age-adjusted per 100,000 US standard population.  
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International 
Classification of Diseases, 10th Revision (ICD-10) codes B17.1 and B18.2 (hepatitis C).  
§Included white, non-Hispanic and white Hispanic.  
¶Included black, non-Hispanic and black Hispanic.  
**Included all other racial/ethnic groups. 
 
Source: CDC. National Vital Statistics System.  
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• Of the three types of viral hepatitis (hepatitis A, B, and C), hepatitis C accounted for the 
most deaths and had the highest death rate. 
• From 2007 through 2011, the mortality rate of hepatitis C increased from 4.6 deaths per 
100,000 population in 2007 to 4.8 deaths per 100,000 population in 2011. 
• In 2007, the highest mortality rates were observed among persons aged 45–54 years and 
55-64 years and the rates were similar (13.5 and 15.7 deaths per 100,000 population, 
respectively). 
• From 2007 through 2011, mortality rates of persons with hepatitis C increased 39% 
among persons aged 55–64 years to a rate of 21.9 deaths per 100,000 population in 2011. 
• In 2011, the highest mortality rates of persons with hepatitis C by race/ethnicity and sex 
were observed among American Indians and Alaska Natives (10.6 deaths per 100,000 
population) and males (7.1 deaths per 100,000 population) respectively. 
 
DISCUSSION 
National surveillance data for acute viral hepatitis provide essential information for identifying 
patterns and trends in viral hepatitis; providing data for national and local estimates of the health 
burden of hepatitis A, B, and C; targeting groups for whom public health intervention is needed; 
and evaluating intervention efforts. National rates for acute hepatitis A and B have been 
published since 1966, and national rates for acute hepatitis C (formerly non-A, non-B) have been 
published since 1992. Major changes in the epidemiology of these diseases have occurred since 
reporting of these infections was initiated, largely resulting from implementation of prevention 
strategies, including the introduction of effective vaccines against hepatitis A and hepatitis B. 
NNDSS, the core of viral hepatitis surveillance, was designed to enable states to notify CDC of 
infectious diseases diagnosed with a single positive laboratory test. Cases of acute and chronic 
hepatitis B and C do not fit this pattern, as additional information beyond a single laboratory test 
is required to confirm a case (1). To better count and characterize cases of viral hepatitis and 
estimate the burden of disease, CDC supplements NNDSS data with data obtained from select 
funded sites, national surveys, and vital statistics. 
Data from NNDSS indicate declining rates of acute hepatitis A, acute hepatitis B, and acute 
hepatitis C during 1995–2010. More recent data show the rate of decline has decreased, and 
incidence has become relatively stable for acute hepatitis A and B, whereas a marked increase in 
the number of cases of acute hepatitis C was in 2011 and 2012. Still, most new infections with 
HAV, HBV, and HCV remain undetected and unreported. In 2012, after adjusting for 
asymptomatic cases and underreporting, the estimated number of cases of HAV, HBV, and HCV 
infections was approximately 3,050, 18,760, and 21,870, respectively. As noted in “Adjustments 
to Reported Cases” (page 16), these estimates cannot be compared directly with estimates from 
previous years which were based on different methods of calculation. 
Despite decreases in acute viral hepatitis, chronic hepatitis infection continues to affect millions 
of Americans. In the United States, an estimated 700,000–1.4 million persons are living with 
chronic hepatitis B infection (2, 3), and an estimated 2.7–3.9 million persons are chronically 
infected with hepatitis C (4). In 2012, over 40,000 reports of chronic hepatitis B and over 
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145,000 reports of chronic hepatitis C were submitted to CDC through NNDSS. Of these, 24,950 
reports of chronic hepatitis B infection and 64,370 reports of chronic hepatitis C infections were 
available for descriptive analyses. Mortality data from 2011, the latest year for which these data 
were available, reveal the serious health consequences associated with viral hepatitis: chronic 
liver disease, including cirrhosis, was the 12th leading cause of death in the United States in 
2011 (5). Viral hepatitis-associated death rates in 2011 were highest among persons infected with 
HCV (4.82 deaths per 100,000 population), followed by HBV (0.52 deaths per 100,000 
population), and HAV (0.02 deaths per 100,000 population) (6). 
CDC and state health departments rely on surveillance data to track the incidence of acute 
infection, guide development and evaluation of programs and policies designed to prevent 
infection and minimize the public health impact of viral hepatitis, and monitor progress towards 
achieving goals established for these programs and policies. Effective systems for conducting 
surveillance for chronic HBV and HCV infections are needed to ensure accurate reporting of all 
cases and to support and evaluate prevention activities. Additional investments in surveillance at 
the local, state, and national levels are essential to build strong prevention programs that interrupt 
transmission of viral hepatitis and improve the health of those who are already infected. 
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ADDITIONAL RESOURCES 
Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course 
Textbook. 
• Hepatitis A: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepa.pdf [PDF - 
14 Pages] 
• Hepatitis B: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf [PDF - 
24 Pages] 
Prevention of Hepatitis A through Active or Passive Immunization: Recommendations of the 
Advisory Committee on Immunization Practices (ACIP): 
http://www.cdc.gov/mmwr/pdf/rr/rr5507.pdf [PDF - 30 Pages] 
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus 
Infection in the United States — Part I: Immunization of Infants, Children, and Adolescents: 
http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf [PDF - 39 Pages] 
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus 
Infection in the United States — Part II: Immunization of Adults: 
http://www.cdc.gov/mmwr/PDF/rr/rr5516.pdf [PDF - 40 Pages] 
Recommendations for Identification and Public Health Management of Persons with Chronic 
Hepatitis B Virus Infection: http://www.cdc.gov/mmwr/pdf/rr/rr5708.pdf [PDF - 28 Pages] 
Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-
Related Chronic Disease: http://www.cdc.gov/mmwr/PDF/RR/RR4719.pdf [PDF - 54 Pages] 
2005 Guidelines for Viral Hepatitis Surveillance and Case Management: 
http://www.cdc.gov/hepatitis/PDFs/2005Guidlines-Surv-CaseMngmt.pdf  
 
